Royalty Report: Delivery, Medical, Drugs – Collection: 294272

$150.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 6

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 6

Primary Industries

  • Delivery
  • Medical
  • Drugs
  • Device
  • implants
  • Drug Discovery
  • Parkinsons Disease

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 294272

License Grant
The University grants an exclusive, world-wide license to make, have made, use, import, offer for sale and sell Licensed Products in the Field .
License Property
The University has intellectual property relating to surgically implantable drug delivery systems.

The patents include Polymer-based Surgically Implantable Haloperidol Delivery Systems and Methods for Their Production and Use, and, Drug Containing Implants and Methods of Use Thereof.

M2281    Polymer-based Surgically Implantable Haloperidol Delivery Systems and Methods for Their Production and Use  60/242,304

Q3399-PCT    Long-Term Delivery Formulations and Methods of Use Thereof  US05/00884

S4072    Drug-Containing Implants and Methods od Use Thereof  11/183,232

S4084    Drug containing Implants and Methods of Use Thereof  11/195,845

S4236    Ropinerol Implants for the Treatment of Parkinson’s Disease  S No. 60/789,961

Field of Use
The license from University patent applications and other intellectual property related to the LAD technology to develop and commercialize licensed products

LAD to improve the control, consistency and convenience of medication delivery. LAD is comprised of a biodegradable polymer matrix using commonly available medical polymers and an active drug. It is formed into a small implant for injection just below the skin. We designed LAD to improve the control, consistency and convenience of medication delivery.

IPSCIO Record ID: 298788

License Grant
This amendment adds a patent to the license.
License Property
LAD to improve the control, consistency and convenience of medication delivery. LAD is comprised of a biodegradable polymer matrix using commonly available medical polymers and an active drug. It is formed into a small implant for injection just below the skin. We designed LAD to improve the control, consistency and convenience of medication delivery.
Field of Use
The patent is for Implants for the Treatment of Dopamine Associated States, known as the Ropinirole Patent.

Ropinirole is used to treat symptoms of Parkinson's disease (stiffness, tremors, muscle spasms, and poor muscle control). Ropinirole is also used to treat restless legs syndrome (RLS).

IPSCIO Record ID: 294293

License Grant
Licensor grants an exclusive, worldwide license under the Licensor IP Rights, Licensor Research IP Rights, and Licensors rights under the Joint Research IP Rights to develop, make, have made, use, offer for sale, sell, have sold, export and import the Product for use in the Field.
License Property
The Product shall mean a biodegradable, preformed, macroscopic implant device consisting of the Active Agent, as the sole active pharmaceutical ingredient, incorporated into the Delivery Matrix.

The joint research is for Implants for the treatment of dopamine associated states, meaning Biodegradable implant containing a dopamine modluating compound.

Licensor patents include Methods for manufacturing delivery systems and systems, and, Modulating burst and release profiles from coestruded implants by treating implant ends, and, Influencing drug release  profiles from implants by selectively adjusting the location and amount of drug loading, and, Implant devices that differ by release profile and methods of making and using same.

Field of Use
Parties have been collaborating since on the development of a biodegradable sustained release formulation of an approved dopamine agonist. The result is Licensee’s NP201, the first long-acting treatment available in broadly acceptable dose form that maintains the potential to provide sustained relief from Parkinson’s disease without motor response complications. NP201 leverages Licensee’s long-acting delivery (LAD™) technology and Licensee’s proprietary biodegradable polymer matrix implant technology to achieve optimal drug release over an extended period of time.

IPSCIO Record ID: 294273

License Grant
Licensor will undertake the Project exclusively for Licensee.  The purpose of the Project is to develop the Product.

Licensor will grant an exclusive license to Licensors interest in Research Inventions and Licensors Technology, including, without limitation, all know how and present and future patents, patent applications, certificates of invention, or applications for certificates of invention and any supplemental protection certificates together with any extensions, registrations, confirmations, reissues, substitutions, divisions, continuations or continuations-in-part, reexamination or renewals thereof to the extent necessary for Licensee to make, have made, use, import, sell, have sold and offer for sale the Product in the Field in the Territory.

Licensor grants an exclusive option to license Licensors interest in Research Inventions and Licensor Technology necessary to make, have made, use and sell the Product developed.

With respect to the Project, Licensor shall provide the services of such personnel, laboratory facilities, equipment, chemicals, and other supplies as are required to conduct its activities under this agreement.

License Property
The Product is Injectable, biodegradable implant (single preformed macroscopic device) formulation of the Active Agent for the treatment of Parkinsons Disease and/or Restless Leg Syndrome in humans.

Licensors patent is for  Methods for Manufacturing delivery Systems and Systems Thereof.

Licensors technology includes:
• Designing and developing depot formulations and devices with biodegradable polymers and non-biodegradable polymers.
• Microparticle compositions to achieve sustained release.
• Nanoparticle compositions to increase bioavailability (includes polymeric and lipid excipients).
• Process technology (laboratory scale, pilot scale, and manufacturing) to fabricate depot formulations, including microparticles.
• Analytical testing useful for the development and registration of depot formulations and devices.
• Design and synthesis of biodegradable polymers.
• Attachment of small molecules and macromolecules to biodegradable polymers]

Field of Use
The product field of use is for the treatment of Parkinsons Disease and/or Restless Leg Syndrome in humans.  The agreement field of use is prevention, treatment or control of any human or animal condition, disease or physiological function.

Licensee designed NP201 to provide continuous delivery of Parkinson’s disease medication in an easy to administer andtolerable dose formulation. After administration, NP201 isdesigned to slowly release ropinirole, an FDA approvedmedication. Based on data from our preclinical studies, webelieve that NP201 has the potential to provide continuoussymptomatic relief for up to two months per dose and tosignificantly decrease the incidence of adverse eventsassociated with current treatments.

IPSCIO Record ID: 282943

License Grant
The Netherlands Licensee hereby grants to Licensor, and Licensor hereby accepts, the right of first refusal to be granted a license under all future patents and patent applications in connection with the PolyActive Technology for the non-exclusive use by Licensor of the PolyActive Technology in the Orthopedic Field and/or for use as a medical device not containing a biological active agent(s). Such right will be subject to a royalty.

Licensee grants to Licensor and Licensor accepts, as from the Effective Date, an exclusive, unlimited, world-wide, perpetual, royalty-free license, with the right to grant sub-licenses to make, use, sell, market and develop any PolyActive Rights B relating to osseouschondral and/or osteochondral plugs, fillers, cement restrictors, or the like, including but not limited to SynPlug(TM) (Licensee License B.)

Licensee grants to Licensor and Licensor accepts, as from the Effective Date, an exclusive, unlimited, world-wide, perpetual, royalty-free license, with the right to grant sub-licenses to make, use, sell, market and develop any PolyActive Rights A and/or PolyActive Rights B related to the use of the PolyActive Technology in a medical device to be used to measure and/or monitor blood glucose (Licensor License AB).

License Property
PolyActive Technology shall mean a drug delivery system controlling the release of biologically active molecules, which is based on PolyActive. Products based on PolyActive Technology can be used for both local and systemic administration, and have applications in pharmaceutics and medical technology.

PolyActive shall mean a biodegradable (amphiphilic) poly(ether-ester) multiblock copolymer based on PEGT and PBT.

CHIENNA-Patents shall mean the patents and patent applications defined and listed in Annex I(A) to the ACLA.

PolyActive Rights A shall mean the PolyActive Rights A as defined and listed in Annex 3.2, consisting of the CHIENNA-Patents but not including all previously abandoned and/or transferred patents and patent applications.

6,685,957 – Preparation of fibrous polymer implant containing bioactive agents using wet spinning technique
5,980,948 – Polyetherester copolymers as drug delivery matrices

PolyActive Rights B Shall mean the PolyActive Rights B as defined and listed in Annex 3.1, consisting of the Licensor-Patents but not including (1) all previously abandoned and/or transferred patents and patent applications; (2) the Osteoinduction patent family; and (3) the Cement Restrictor 4th Design.

6,479,418 – Porous ceramic body
6,069,295 – Implant material

Field of Use
PolyActive is a biodegradable polymeric drug delivery system.  Licensee uses PolyActive to develop its controlled-release alfa interferon product LocteronTM.

Locteron is a controlled release formulation of interferon alfa for the treatment of chronic hepatitis C, currently in Phase IIa studies.

Orthopedic Field shall mean that part of the Licensees patents and patent application which relate to a therapeutic application to the musculoskeletal system, including bone, cartilage, joints, related connective tissues, ligaments, tendons and nerves.

PolyActive technology and its intellectual property in certain strategic areas, including additional applications in orthopedics.

IPSCIO Record ID: 256301

License Grant
Australian Licensor grants
— an exclusive, even as to Licensor, worldwide license, with the right to sublicense, under the Licensor Technology, the Licensor Program Technology, and the Licensor Confidential Information and
— an exclusive, even as to Licensor, royalty-bearing worldwide sublicense, with a right of further sublicense, under the Licensed University Technology, in each case to make, have made, use, sell or import Licensed Products, Devices and Formulations in the Territory in the Field; and,
—  an exclusive, even as to Licensor, worldwide license, with the right to sublicense, under the Licensor Patent Rights, and the Licensor Program Patent Rights and
—  an exclusive, even as to Licensor, worldwide sublicense, with a right of further sublicense, under the Licensed University Patent Rights, in each case to make, have made, use, sell or import Licensed Products, Devices and Formulations in the Territory in the Field; and,
—  a non-exclusive sublicense, without a right to further sublicense, to use the Licensor Trademarks with the Licensed Products, Devices and Formulations in the Territory in the Field.
License Property
Licensor owns or otherwise controls certain patents, patent applications, technology, know-how and scientific and technical information relating to formulations for drug delivery and compatible devices, including Medidurâ„¢.

Licensor has extensive expertise in designing and developing innovative ophthalmic drug delivery systems.

Medidur is a tiny injectable, non-erodible, intravitreal device for the treatment of Diabetic Macular Edema (DME), which can lead to blindness. The implant is injected into the back of the eye in an office setting rather than a surgical one. It releases a constant amount of drug and lasts between 18 to 36 months.

Field of Use
The Field means the delivery of formulations for the treatment, control or prevention of any ophthalmic diseases and conditions in humans or animals.

The Licensees Compound means any composition of matter, including, small and large molecules, therapeutic proteins, polynucleotides, both double-stranded and singlestranded, and antibodies, or biosimilars.

Collaborative research and license agreement is for Licensor’s controlled drug delivery technologies, including the MedidurTM technology, in ophthalmic applications.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.